US Prosecutors Seek 8-Year Sentence for Indian-Origin Fund Manager Martoma
An Indian-origin portfolio manager, convicted for his role as the "central figure" in one of the most lucrative insider trading schemes in US history, should be sentenced to more than eight years in prison, Manhattan's top federal prosecutor Preet Bharara has said.
Mathew Martoma, 39, was convicted in February of one count of conspiracy to commit securities fraud and two counts of securities fraud.
A former portfolio manager of CR Intrinsic Investors, a division of hedge fund giant SAC Capital, Mr Martoma will be sentenced on July 28 and faces a maximum of 20 years in prison.
Ahead of the sentencing, India-born Mr Bharara asked the federal court in New York to sentence Mr Martoma to more than eight years in prison for collecting confidential information about a high-profile drug trial and making profits and avoiding losses of $275 million for SAC Capital.
Mr Martoma, a father of three, even earned a $9.3 million bonus for himself due to his various trades for SAC.
"Martoma was the central figure in the most lucrative insider trading scheme ever charged. Over a period of approximately 18 months, the defendant cultivated and corrupted two doctors legally bound to guard confidential information concerning a high-profile drug trial, ultimately obtaining an advance preview of the highly anticipated public announcement of the results," Mr Bharara said in the government's sentencing memorandum submitted in court on Friday.
Mr Bharara alleged that Mr Martoma's entire success in his four years at SAC Capital was based on illegal insider trading.
Days after beginning his employment at SAC Capital, Mr Martoma began searching for doctors who would be willing to provide him access to confidential information about an Alzheimer's disease drug trial conducted by Elan Pharmaceuticals and Wyeth Corporation.
Mr Bharara said Mr Martoma caused approximately $750 million worth of Elan and Wyeth securities to be traded based on the illegal inside information, netting profits and avoiding losses of $275 million for SAC Capital.
According to federal sentencing guidelines, Mr Martoma faces a 15- to 19-year prison term.
Mr Bharara said while the government does not oppose a sentence below the 15-19 years range, Mr Martoma should be given "a sentence that nevertheless includes a substantial period of incarceration that is commensurate with the seriousness of the offense conduct and the unprecedented ill-gotten gains that it generated".
"A significant period of imprisonment toward the high end of the insider trading sentences imposed by courts in this District - and above Probation's recommendation of 96 months - is warranted," Mr Bharara said.
"Martoma's role in the offence was central. Martoma was not a passive recipient of inside information; he urged those with duties to Elan and Wyeth to share with him information that breached these duties," Mr Bharara said, rejecting claims made by Mr Martoma' defence that he had "dedicated himself to a lifetime of (good work) and giving".
"Martoma's post-graduate working life has been limited to highly-paid work for hedge funds. The bulk of Martoma's earnings from his hedge fund career - the entirety of his $9 million bonus from SAC Capital - were the proceeds of securities fraud," Mr Bharara said.
Federal prosecutors also noted in the sentencing memorandum that Mr Martoma had been expelled from Harvard University in 1999 for allegedly doctoring his law school transcript to try to gain a federal clerkship.
Mr Martoma had even changed his name from Ajai Mathew Thomas before applying to Stanford University, where no one knew that he had been expelled from Harvard. Following his conviction, Mr Martoma was stripped of his MBA degree by Stanford business school, the first time the prestigious US institution has revoked a graduate's degree.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.